Innovation
Too few truly great innovations for congenital heart defects ever get the chance to reach patients. We’re out to change that.
Our innovation work accelerates new therapies from idea to impact. We are supporting technologies and programs from their earliest stages and giving startups and innovators the resources and guidance they need to get their concepts across the finish line to patients.
Safeguarding and expanding access to existing innovations is another focus. We are working to keep existing technologies within reach of the patients and clinicians who need them. And we are finding new ways to standardize and scale proven technologies so more patients can access them.
P3-CHD
Our national collaborative is scaling and standardizing personalized 3D heart modeling and virtual surgical planning tools so that they can be used in patient care across a broader network of children’s hospitals. Run by leaders from Boston Children’s Hospital, Stanford Medicine, and Children’s Hospital of Philadelphia, the collaborative offers hospitals without in-house capabilities the opportunity to draw on expertise from the three institutions, and contribute to the development of a standardized software platform built specifically for CHD care.


Early Innovation Research Grants
We’re funding the bold, early-stage science and engineering research that could lead to the next generation of treatments for congenital heart defects. We launched our first RFP for blue sky therapeutics in 2026, with several more innovation RFPs launching in 2027.
Strategic Partnerships and Collaboration
We’re working with manufacturers of products that are already on the market and being used for CHD today to ensure they remain available for clinical use, continue to be innovated upon, and get regulatory approval for CHD as needed.


CHD Startup Accelerator
More coming soon!

